At the forefront of therapies for rare and orphan diseasesTM
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events

Home >> Investor Relations >> Investor Relations

Investor Relations

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.

View all »Recent Releases

Apr 9, 2015
Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day

Mar 19, 2015
Amicus Therapeutics Provides Positive Global Regulatory Updates From EMA and FDA Meetings for Fabry Monotherapy

View all »Events & Presentations

Mar 19, 2015 at 8:00 AM ET
Fabry Monotherapy Global Regulatory Update

Mar 3, 2015 at 5:00 PM ET
Amicus Full-Year 2014 Results Conference Call and Webcast

Copyright © 2015 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy